Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using <scp>WST</scp> 11‐vascular‐targeted photodynamic ( <scp>VTP</scp> ) therapy

Abstract

Treatment with 4 mg/kg TOOKAD Soluble activated by 753 nm light at a dose of 200 J/cm and an LDI of >1 resulted in treatment effect in 95% of the planned treatment volume and a negative biopsy rate at 6 months of 10/12 men (83%).